# SOHO-02 (NCT06452277)

> A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06452277
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Bayer
- Conditions: Advanced Non-small Cell Lung Cancer, HER2 Mutation
- Interventions: Sevabertinib; Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed
- Enrollment: 555
- Primary outcome: Progression free survival (PFS) per RECIST 1.1 as assessed by BICR

## Commentary we found

- YouTube: 12
- X threads: 12
- Podcasts: 8

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=soho-02-nct06452277

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06452277", "email": "<work email>"}; the inbox owner confirms by the emailed link.